# Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy

> **NCT00468286** · PHASE2 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 133 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Degarelix
- **DRUG:** Degarelix

## Key facts

- **NCT ID:** NCT00468286
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2011-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00468286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00468286, "Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00468286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*